产品展示
优质供应
详细内容
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
慧嘉生物您实验身边的好伙伴
为客户提供“质量的产品”和“*优质的服务”
为客户提供“质量的产品”和“*优质的服务”
为客户提供“质量的产品”和“*优质的服务”
为客户提供“质量的产品”和“*优质的服务”
为客户提供“质量的产品”和“*优质的服务”
欢迎广大客户咨询，另有大量宣传海报和小礼品赠送。
联系电话：
传 真：
Q Q：
邮 箱：sale@biohj.com
SOX9 Human/重组人SOX9
产品编号：PRO-738
产品规格：2μg/5μg/10μg
Synonyms SOX-9, SRY （sex determining region Y）-box 9 （campomelic dysplasia, autosomal sex-reversal）, Transcription factor SOX-9, SOX9, CMD1, SRA1, CMPD1. Introduction SOX9 is involved in skeletal development. SOX9 regulates the expression of other genes which play a role in chondrogenesis by performing as a transcription factor for these genes. SOX9 takes part in chondrocyte differentiation and, together with steroidogenic factor 1; SOX9 regulates transcription of the anti-Muellerian hormone gene.
Deficiencies of SOX9 result in skeletal malformation syndrome campomelic dysplasia, often with sex reversal. SOX9 is a transcription factor having vast mobility group DNA-binding domain that is expressed in all prechondrocytic ａnd chondrocytic cells throughout embryonic growth. SOX9 Phosphorylation by PKA raises its DNA binding ａnd transcriptional activity. SOX9 controls expression of chondrocyte phenotype related genes. IL-1 ａnd TNF-a decrease SOX9 levels of mRNA and/or protein in chondrocytes, therefore strongly inhibit the expression of genes for cartilage extracellular matrix proteins. SOX9 down-regulation takes part in inhibiting expression of the cartilage phenotype in inflammatory joint diseases. Description SOX9 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 195 amino acids （316-510 a.a.） fused to a GST tag ａnd having a total molecular mass of 48kDa.
The SOX9 is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation SOX9 is supplied in 50mM Tris-Acetate, pH-7.5, 1mM EDTA ａnd 20% Glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
SOX9 Human/重组人SOX9
产品编号：PRO-738
产品规格：2μg/5μg/10μg
Synonyms SOX-9, SRY （sex determining region Y）-box 9 （campomelic dysplasia, autosomal sex-reversal）, Transcription factor SOX-9, SOX9, CMD1, SRA1, CMPD1. Introduction SOX9 is involved in skeletal development. SOX9 regulates the expression of other genes which play a role in chondrogenesis by performing as a transcription factor for these genes. SOX9 takes part in chondrocyte differentiation and, together with steroidogenic factor 1; SOX9 regulates transcription of the anti-Muellerian hormone gene.
Deficiencies of SOX9 result in skeletal malformation syndrome campomelic dysplasia, often with sex reversal. SOX9 is a transcription factor having vast mobility group DNA-binding domain that is expressed in all prechondrocytic ａnd chondrocytic cells throughout embryonic growth. SOX9 Phosphorylation by PKA raises its DNA binding ａnd transcriptional activity. SOX9 controls expression of chondrocyte phenotype related genes. IL-1 ａnd TNF-a decrease SOX9 levels of mRNA and/or protein in chondrocytes, therefore strongly inhibit the expression of genes for cartilage extracellular matrix proteins. SOX9 down-regulation takes part in inhibiting expression of the cartilage phenotype in inflammatory joint diseases. Description SOX9 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 195 amino acids （316-510 a.a.） fused to a GST tag ａnd having a total molecular mass of 48kDa.
The SOX9 is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation SOX9 is supplied in 50mM Tris-Acetate, pH-7.5, 1mM EDTA ａnd 20% Glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
SOX9 Human/重组人SOX9
产品编号：PRO-738
产品规格：2μg/5μg/10μg
Synonyms SOX-9, SRY （sex determining region Y）-box 9 （campomelic dysplasia, autosomal sex-reversal）, Transcription factor SOX-9, SOX9, CMD1, SRA1, CMPD1. Introduction SOX9 is involved in skeletal development. SOX9 regulates the expression of other genes which play a role in chondrogenesis by performing as a transcription factor for these genes. SOX9 takes part in chondrocyte differentiation and, together with steroidogenic factor 1; SOX9 regulates transcription of the anti-Muellerian hormone gene.
Deficiencies of SOX9 result in skeletal malformation syndrome campomelic dysplasia, often with sex reversal. SOX9 is a transcription factor having vast mobility group DNA-binding domain that is expressed in all prechondrocytic ａnd chondrocytic cells throughout embryonic growth. SOX9 Phosphorylation by PKA raises its DNA binding ａnd transcriptional activity. SOX9 controls expression of chondrocyte phenotype related genes. IL-1 ａnd TNF-a decrease SOX9 levels of mRNA and/or protein in chondrocytes, therefore strongly inhibit the expression of genes for cartilage extracellular matrix proteins. SOX9 down-regulation takes part in inhibiting expression of the cartilage phenotype in inflammatory joint diseases. Description SOX9 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 195 amino acids （316-510 a.a.） fused to a GST tag ａnd having a total molecular mass of 48kDa.
The SOX9 is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation SOX9 is supplied in 50mM Tris-Acetate, pH-7.5, 1mM EDTA ａnd 20% Glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
SOX9 Human/重组人SOX9
产品编号：PRO-738
产品规格：2μg/5μg/10μg
Synonyms SOX-9, SRY （sex determining region Y）-box 9 （campomelic dysplasia, autosomal sex-reversal）, Transcription factor SOX-9, SOX9, CMD1, SRA1, CMPD1. Introduction SOX9 is involved in skeletal development. SOX9 regulates the expression of other genes which play a role in chondrogenesis by performing as a transcription factor for these genes. SOX9 takes part in chondrocyte differentiation and, together with steroidogenic factor 1; SOX9 regulates transcription of the anti-Muellerian hormone gene.
Deficiencies of SOX9 result in skeletal malformation syndrome campomelic dysplasia, often with sex reversal. SOX9 is a transcription factor having vast mobility group DNA-binding domain that is expressed in all prechondrocytic ａnd chondrocytic cells throughout embryonic growth. SOX9 Phosphorylation by PKA raises its DNA binding ａnd transcriptional activity. SOX9 controls expression of chondrocyte phenotype related genes. IL-1 ａnd TNF-a decrease SOX9 levels of mRNA and/or protein in chondrocytes, therefore strongly inhibit the expression of genes for cartilage extracellular matrix proteins. SOX9 down-regulation takes part in inhibiting expression of the cartilage phenotype in inflammatory joint diseases. Description SOX9 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 195 amino acids （316-510 a.a.） fused to a GST tag ａnd having a total molecular mass of 48kDa.
The SOX9 is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation SOX9 is supplied in 50mM Tris-Acetate, pH-7.5, 1mM EDTA ａnd 20% Glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
SOX9 Human/重组人SOX9
产品编号：PRO-738
产品规格：2μg/5μg/10μg
Synonyms SOX-9, SRY （sex determining region Y）-box 9 （campomelic dysplasia, autosomal sex-reversal）, Transcription factor SOX-9, SOX9, CMD1, SRA1, CMPD1. Introduction SOX9 is involved in skeletal development. SOX9 regulates the expression of other genes which play a role in chondrogenesis by performing as a transcription factor for these genes. SOX9 takes part in chondrocyte differentiation and, together with steroidogenic factor 1; SOX9 regulates transcription of the anti-Muellerian hormone gene.
Deficiencies of SOX9 result in skeletal malformation syndrome campomelic dysplasia, often with sex reversal. SOX9 is a transcription factor having vast mobility group DNA-binding domain that is expressed in all prechondrocytic ａnd chondrocytic cells throughout embryonic growth. SOX9 Phosphorylation by PKA raises its DNA binding ａnd transcriptional activity. SOX9 controls expression of chondrocyte phenotype related genes. IL-1 ａnd TNF-a decrease SOX9 levels of mRNA and/or protein in chondrocytes, therefore strongly inhibit the expression of genes for cartilage extracellular matrix proteins. SOX9 down-regulation takes part in inhibiting expression of the cartilage phenotype in inflammatory joint diseases. Description SOX9 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 195 amino acids （316-510 a.a.） fused to a GST tag ａnd having a total molecular mass of 48kDa.
The SOX9 is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation SOX9 is supplied in 50mM Tris-Acetate, pH-7.5, 1mM EDTA ａnd 20% Glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
SOX9 Human/重组人SOX9
产品编号：PRO-738
产品规格：2μg/5μg/10μg
Synonyms SOX-9, SRY （sex determining region Y）-box 9 （campomelic dysplasia, autosomal sex-reversal）, Transcription factor SOX-9, SOX9, CMD1, SRA1, CMPD1. Introduction SOX9 is involved in skeletal development. SOX9 regulates the expression of other genes which play a role in chondrogenesis by performing as a transcription factor for these genes. SOX9 takes part in chondrocyte differentiation and, together with steroidogenic factor 1; SOX9 regulates transcription of the anti-Muellerian hormone gene.
Deficiencies of SOX9 result in skeletal malformation syndrome campomelic dysplasia, often with sex reversal. SOX9 is a transcription factor having vast mobility group DNA-binding domain that is expressed in all prechondrocytic ａnd chondrocytic cells throughout embryonic growth. SOX9 Phosphorylation by PKA raises its DNA binding ａnd transcriptional activity. SOX9 controls expression of chondrocyte phenotype related genes. IL-1 ａnd TNF-a decrease SOX9 levels of mRNA and/or protein in chondrocytes, therefore strongly inhibit the expression of genes for cartilage extracellular matrix proteins. SOX9 down-regulation takes part in inhibiting expression of the cartilage phenotype in inflammatory joint diseases. Description SOX9 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 195 amino acids （316-510 a.a.） fused to a GST tag ａnd having a total molecular mass of 48kDa.
The SOX9 is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation SOX9 is supplied in 50mM Tris-Acetate, pH-7.5, 1mM EDTA ａnd 20% Glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
SOX9 Human/重组人SOX9
产品编号：PRO-738
产品规格：2μg/5μg/10μg
Synonyms SOX-9, SRY （sex determining region Y）-box 9 （campomelic dysplasia, autosomal sex-reversal）, Transcription factor SOX-9, SOX9, CMD1, SRA1, CMPD1. Introduction SOX9 is involved in skeletal development. SOX9 regulates the expression of other genes which play a role in chondrogenesis by performing as a transcription factor for these genes. SOX9 takes part in chondrocyte differentiation and, together with steroidogenic factor 1; SOX9 regulates transcription of the anti-Muellerian hormone gene.
Deficiencies of SOX9 result in skeletal malformation syndrome campomelic dysplasia, often with sex reversal. SOX9 is a transcription factor having vast mobility group DNA-binding domain that is expressed in all prechondrocytic ａnd chondrocytic cells throughout embryonic growth. SOX9 Phosphorylation by PKA raises its DNA binding ａnd transcriptional activity. SOX9 controls expression of chondrocyte phenotype related genes. IL-1 ａnd TNF-a decrease SOX9 levels of mRNA and/or protein in chondrocytes, therefore strongly inhibit the expression of genes for cartilage extracellular matrix proteins. SOX9 down-regulation takes part in inhibiting expression of the cartilage phenotype in inflammatory joint diseases. Description SOX9 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 195 amino acids （316-510 a.a.） fused to a GST tag ａnd having a total molecular mass of 48kDa.
The SOX9 is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation SOX9 is supplied in 50mM Tris-Acetate, pH-7.5, 1mM EDTA ａnd 20% Glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
SOX9 Human/重组人SOX9
产品编号：PRO-738
产品规格：2μg/5μg/10μg
Synonyms SOX-9, SRY （sex determining region Y）-box 9 （campomelic dysplasia, autosomal sex-reversal）, Transcription factor SOX-9, SOX9, CMD1, SRA1, CMPD1. Introduction SOX9 is involved in skeletal development. SOX9 regulates the expression of other genes which play a role in chondrogenesis by performing as a transcription factor for these genes. SOX9 takes part in chondrocyte differentiation and, together with steroidogenic factor 1; SOX9 regulates transcription of the anti-Muellerian hormone gene.
Deficiencies of SOX9 result in skeletal malformation syndrome campomelic dysplasia, often with sex reversal. SOX9 is a transcription factor having vast mobility group DNA-binding domain that is expressed in all prechondrocytic ａnd chondrocytic cells throughout embryonic growth. SOX9 Phosphorylation by PKA raises its DNA binding ａnd transcriptional activity. SOX9 controls expression of chondrocyte phenotype related genes. IL-1 ａnd TNF-a decrease SOX9 levels of mRNA and/or protein in chondrocytes, therefore strongly inhibit the expression of genes for cartilage extracellular matrix proteins. SOX9 down-regulation takes part in inhibiting expression of the cartilage phenotype in inflammatory joint diseases. Description SOX9 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 195 amino acids （316-510 a.a.） fused to a GST tag ａnd having a total molecular mass of 48kDa.
The SOX9 is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation SOX9 is supplied in 50mM Tris-Acetate, pH-7.5, 1mM EDTA ａnd 20% Glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
SOX9 Human/重组人SOX9
产品编号：PRO-738
产品规格：2μg/5μg/10μg
Synonyms SOX-9, SRY （sex determining region Y）-box 9 （campomelic dysplasia, autosomal sex-reversal）, Transcription factor SOX-9, SOX9, CMD1, SRA1, CMPD1. Introduction SOX9 is involved in skeletal development. SOX9 regulates the expression of other genes which play a role in chondrogenesis by performing as a transcription factor for these genes. SOX9 takes part in chondrocyte differentiation and, together with steroidogenic factor 1; SOX9 regulates transcription of the anti-Muellerian hormone gene.
Deficiencies of SOX9 result in skeletal malformation syndrome campomelic dysplasia, often with sex reversal. SOX9 is a transcription factor having vast mobility group DNA-binding domain that is expressed in all prechondrocytic ａnd chondrocytic cells throughout embryonic growth. SOX9 Phosphorylation by PKA raises its DNA binding ａnd transcriptional activity. SOX9 controls expression of chondrocyte phenotype related genes. IL-1 ａnd TNF-a decrease SOX9 levels of mRNA and/or protein in chondrocytes, therefore strongly inhibit the expression of genes for cartilage extracellular matrix proteins. SOX9 down-regulation takes part in inhibiting expression of the cartilage phenotype in inflammatory joint diseases. Description SOX9 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 195 amino acids （316-510 a.a.） fused to a GST tag ａnd having a total molecular mass of 48kDa.
The SOX9 is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation SOX9 is supplied in 50mM Tris-Acetate, pH-7.5, 1mM EDTA ａnd 20% Glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
SOX9 Human/重组人SOX9
产品编号：PRO-738
产品规格：2μg/5μg/10μg
Synonyms SOX-9, SRY （sex determining region Y）-box 9 （campomelic dysplasia, autosomal sex-reversal）, Transcription factor SOX-9, SOX9, CMD1, SRA1, CMPD1. Introduction SOX9 is involved in skeletal development. SOX9 regulates the expression of other genes which play a role in chondrogenesis by performing as a transcription factor for these genes. SOX9 takes part in chondrocyte differentiation and, together with steroidogenic factor 1; SOX9 regulates transcription of the anti-Muellerian hormone gene.
Deficiencies of SOX9 result in skeletal malformation syndrome campomelic dysplasia, often with sex reversal. SOX9 is a transcription factor having vast mobility group DNA-binding domain that is expressed in all prechondrocytic ａnd chondrocytic cells throughout embryonic growth. SOX9 Phosphorylation by PKA raises its DNA binding ａnd transcriptional activity. SOX9 controls expression of chondrocyte phenotype related genes. IL-1 ａnd TNF-a decrease SOX9 levels of mRNA and/or protein in chondrocytes, therefore strongly inhibit the expression of genes for cartilage extracellular matrix proteins. SOX9 down-regulation takes part in inhibiting expression of the cartilage phenotype in inflammatory joint diseases. Description SOX9 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 195 amino acids （316-510 a.a.） fused to a GST tag ａnd having a total molecular mass of 48kDa.
The SOX9 is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation SOX9 is supplied in 50mM Tris-Acetate, pH-7.5, 1mM EDTA ａnd 20% Glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
SOX9 Human/重组人SOX9
产品编号：PRO-738
产品规格：2μg/5μg/10μg
Synonyms SOX-9, SRY （sex determining region Y）-box 9 （campomelic dysplasia, autosomal sex-reversal）, Transcription factor SOX-9, SOX9, CMD1, SRA1, CMPD1. Introduction SOX9 is involved in skeletal development. SOX9 regulates the expression of other genes which play a role in chondrogenesis by performing as a transcription factor for these genes. SOX9 takes part in chondrocyte differentiation and, together with steroidogenic factor 1; SOX9 regulates transcription of the anti-Muellerian hormone gene.
Deficiencies of SOX9 result in skeletal malformation syndrome campomelic dysplasia, often with sex reversal. SOX9 is a transcription factor having vast mobility group DNA-binding domain that is expressed in all prechondrocytic ａnd chondrocytic cells throughout embryonic growth. SOX9 Phosphorylation by PKA raises its DNA binding ａnd transcriptional activity. SOX9 controls expression of chondrocyte phenotype related genes. IL-1 ａnd TNF-a decrease SOX9 levels of mRNA and/or protein in chondrocytes, therefore strongly inhibit the expression of genes for cartilage extracellular matrix proteins. SOX9 down-regulation takes part in inhibiting expression of the cartilage phenotype in inflammatory joint diseases. Description SOX9 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 195 amino acids （316-510 a.a.） fused to a GST tag ａnd having a total molecular mass of 48kDa.
The SOX9 is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation SOX9 is supplied in 50mM Tris-Acetate, pH-7.5, 1mM EDTA ａnd 20% Glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
SOX9 Human/重组人SOX9
产品编号：PRO-738
产品规格：2μg/5μg/10μg
Synonyms SOX-9, SRY （sex determining region Y）-box 9 （campomelic dysplasia, autosomal sex-reversal）, Transcription factor SOX-9, SOX9, CMD1, SRA1, CMPD1. Introduction SOX9 is involved in skeletal development. SOX9 regulates the expression of other genes which play a role in chondrogenesis by performing as a transcription factor for these genes. SOX9 takes part in chondrocyte differentiation and, together with steroidogenic factor 1; SOX9 regulates transcription of the anti-Muellerian hormone gene.
Deficiencies of SOX9 result in skeletal malformation syndrome campomelic dysplasia, often with sex reversal. SOX9 is a transcription factor having vast mobility group DNA-binding domain that is expressed in all prechondrocytic ａnd chondrocytic cells throughout embryonic growth. SOX9 Phosphorylation by PKA raises its DNA binding ａnd transcriptional activity. SOX9 controls expression of chondrocyte phenotype related genes. IL-1 ａnd TNF-a decrease SOX9 levels of mRNA and/or protein in chondrocytes, therefore strongly inhibit the expression of genes for cartilage extracellular matrix proteins. SOX9 down-regulation takes part in inhibiting expression of the cartilage phenotype in inflammatory joint diseases. Description SOX9 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 195 amino acids （316-510 a.a.） fused to a GST tag ａnd having a total molecular mass of 48kDa.
The SOX9 is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation SOX9 is supplied in 50mM Tris-Acetate, pH-7.5, 1mM EDTA ａnd 20% Glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
产品规格：2μg/5μg/10μg
| Synonyms | SOX-9, SRY （sex determining region Y）-box 9 （campomelic dysplasia, autosomal sex-reversal）, Transcription factor SOX-9, SOX9, CMD1, SRA1, CMPD1. |
| Introduction | SOX9 is involved in skeletal development. SOX9 regulates the expression of other genes which play a role in chondrogenesis by performing as a transcription factor for these genes. SOX9 takes part in chondrocyte differentiation and, together with steroidogenic factor 1; SOX9 regulates transcription of the anti-Muellerian hormone gene. Deficiencies of SOX9 result in skeletal malformation syndrome campomelic dysplasia, often with sex reversal. SOX9 is a transcription factor having vast mobility group DNA-binding domain that is expressed in all prechondrocytic ａnd chondrocytic cells throughout embryonic growth. SOX9 Phosphorylation by PKA raises its DNA binding ａnd transcriptional activity. SOX9 controls expression of chondrocyte phenotype related genes. IL-1 ａnd TNF-a decrease SOX9 levels of mRNA and/or protein in chondrocytes, therefore strongly inhibit the expression of genes for cartilage extracellular matrix proteins. SOX9 down-regulation takes part in inhibiting expression of the cartilage phenotype in inflammatory joint diseases. |
| Description | SOX9 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 195 amino acids （316-510 a.a.） fused to a GST tag ａnd having a total molecular mass of 48kDa. The SOX9 is purified by proprietary chromatographic techniques. |
| Source | Escherichia Coli. |
| Physical Appearance | Sterile Filtered clear solution. |
| Formulation | SOX9 is supplied in 50mM Tris-Acetate, pH-7.5, 1mM EDTA ａnd 20% Glycerol. |
| Stability | Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. Please avoid freeze thaw cycles. |
| Usage | ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals. |
